Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03109756
Other study ID # OV101-16-001
Secondary ID
Status Completed
Phase Phase 1
First received April 6, 2017
Last updated November 29, 2017
Start date April 3, 2017
Est. completion date November 28, 2017

Study information

Verified date September 2017
Source Ovid Therapeutics Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial is a Phase 1 Single Dose PK Study in Adolescent Subjects with Fragile X syndrome (FXS) or Angelman syndrome (AS).

- The primary objective of the study is to evaluate the pharmacokinetics (PK) of OV101 following a single 5 mg dose of OV101 in adolescents with FXS or AS.

- Secondary objectives are to determine the safety and tolerability of a single 5 mg dose of OV101 in adolescents with FXS or AS.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date November 28, 2017
Est. primary completion date November 28, 2017
Accepts healthy volunteers No
Gender All
Age group 13 Years to 17 Years
Eligibility Inclusion Criteria:

1. Adolescents with confirmed clinical and previous molecular diagnosis of FXS or AS, age between 13 to 17 years, inclusive.

2. Subjects must assent to participation in the study (if appropriate), have a parent or legal guardian/representative capable of providing informed consent on behalf of the subject, and commit to participate in all assessments described in the protocol.

3. Subjects must be receiving a stable dose of concomitant medications

4. Subjects should be able to complete study assessments.

5. Subjects who are non-sterile must agree to either remain completely abstinent or to use two effective contraceptive methods from screening until 7 days after the last dose of study treatment.

6. Subjects must have a parent or other reliable caregiver who agrees to accompany the subject at all study visits and provide information about the subject as required by the study protocol, and ensure compliance with the protocol.

Exclusion Criteria:

1. Inability to swallow a capsule.

2. Poorly controlled seizures

3. Clinically significant abnormal ECG at the time of screening.

4. Positive result on serum or urine pregnancy test for women of child-bearing potential (have experienced menarche) who are not using a dual method of contraception (e.g., condoms plus oral contraceptives), with abstinence being an accepted method.

5. Allergy to gaboxadol or any excipients

6. Concomitant cardiovascular, respiratory, liver, renal, or hematologic diseases of a degree that would limit participation in the study

7. History of suicidal behavior or considered a high suicidal risk by the investigator.

8. Any medical, psychological, social disorder(s), or other conditions - including seizure disorder

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
OV101
Single-dose 5 mg OV101

Locations

Country Name City State
United States Ovid Therapeutics Investigative Site Chicago Illinois
United States Ovid Therapeutics Investigative Site Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Ovid Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of maximum plasma concentration achieved following a single dose of OV101 Maximum plasma concentration (Cmax) 10 hours
Primary Measurement of time of maximum plasma concentration following a single dose of OV101 Time after administration of drug when maximum plasma concentration is reached (Tmax) 10 hours
Primary Measurement of plasma half-life following a single dose of OV101 Plasma half-life (T1/2) 10 hours
Primary Measurement of the area under the plasma concentration versus time curve following a single dose of OV101 Area under the curve from 0 to 10 hours (AUC 0-10) 10 hours
Primary Measurement of clearance following a single dose of OV101 Total body clearance (CL) 10 hours
Primary Measurement of the apparent volume of distribution following a single dose of OV101 Apparent volume of distribution during terminal phase (Vz) 10 hours
Secondary Safety parameters, adverse events, absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs, electrocardiogram (ECG) 10 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05418049 - Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT00965432 - A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 Phase 1
Completed NCT01120626 - Randomized Controlled Study of Donepezil in Fragile X Syndrome Phase 2
Completed NCT01204151 - Teaching Math Skills to Individuals With Fragile X Syndrome N/A
Active, not recruiting NCT00334971 - Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women N/A
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Recruiting NCT04977986 - Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome Phase 3
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT03722290 - Metformin in Children and Adults With Fragile X Syndrome Phase 2
Completed NCT05030129 - Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome Phase 2
Recruiting NCT05957549 - Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG N/A
Recruiting NCT04141163 - Metformin in Patients With Fragile X Phase 1/Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Completed NCT00858689 - Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Enrolling by invitation NCT03802799 - Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS Phase 2/Phase 3
Recruiting NCT05295277 - Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT01725152 - Ganaxolone Treatment in Children With Fragile X Syndrome Phase 2